Clinical audit of retinoblastoma management: a retrospective single-institution study

Selvarajah, Arunan; Flegg, Kaitlyn; Sim, Wei Ping; Hu, Jason B.; Gallie, Brenda L.; Shaikh, Furqan; Soliman, Sameh E.; Dimaras, Helen

doi:10.1016/j.jcjo.2021.04.019

Cited by 7 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rb is a kind of ocular malignant tumour with a family genetic predisposition and mostly occurs in infants under 3 years old (28)(29)(30). The main clinical symptoms are intraocular hypertension, vitreous turbidity, corneal edema, intraconjunctival hyperemia and edema, and strabismus (31)(32)(33). In addition, Rb can cause intracranial and distant metastasis, which can easily cause the death of Rb patients, posing a great threat to the quality of life of patients and their offspring (34,35).…”

Section: Discussionmentioning

confidence: 99%

The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma

Huang

Luo

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

目的：研究血浆miR-592和miR-217-3p在视网膜母细胞瘤（Rb）中的异常表达，探讨其表达水平对Rb的临床诊断价值。方法：选取2018年1月至2019年1月到南昌市洪都中医院就诊的100例Rb患者为Rb组，同期来体检中心就诊的100例健康患者为对照组. 采用实时荧光定量PCR（qRT-PCR）检测所有受试者血浆miR-592和miR-217-3p的表达水平；分析血浆miR-592和miR-217-3p水平与Rb临床病理特征的关系；Pearson 相关分析评估了血浆 miR-592 和 miR-217-3p 水平与总生存率之间的关系。结果： Rb组血浆miR-592和miR-217-3p水平显着高于对照组（p < 0.0001），且miR-592的表达与家族遗传史显着相关（p＜ 0.0001)、肿瘤偏倚( p =0.0081)、淋巴结转移( p =0.0048)和病理分级( p =0.0025)，miR-217-3p的表达与家族遗传史显着相关( p＜0.0001)，视神经浸润（p＜0.0001）、淋巴结转移（p = 0.0090）、病理分级（p＜0.0001)。miR-592和miR-217-3p的高表达是Rb更严重的病理表现，随着miR-592（r=-0.2276，p =0.0052）和miR的升高，患者的总生存期显着缩短-217-3p 水平（r=-0.6461，p＜0.0001）。结论： miR-592和miR-217-3p在Rb患者血浆中高表达，其升高的水平呈现Rb严重的病理表现和缩短的总生存期，有望成为Rb临床诊断的生物标志物。

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma

Huang

Luo

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

show abstract

“…Children with retinoblastoma develop tumours in one or both eyes, and about half carry a gene variant that causes retinoblastoma and results in increased risk of a second cancer, as well as the chance of passing it on to their offspring (Dimaras et al 2015). While 96% of Canadian patients survive (Selvarajah et al 2021), survivors live with consequences of the tumours and/or treatment, such as low or no vision in one or both eyes, cosmetic effects or other disruptions such as frequent lifelong follow up.…”

Section: Introductionmentioning

confidence: 99%

EMPOWER Retinoblastoma: Engaging Patient Partners in Solving the Top 10 Priorities for Eye Cancer Research in Canada

Ristevski¹,

Robert²,

Baddeliyanage³

et al. 2022

hcq

Self Cite

View full text Add to dashboard Cite

While it is recognized that research priorities should reflect and integrate the perspectives and needs of patients along with those of health professionals and researchers, it remains challenging to actualize such priorities into tangible research projects. Targeted dissemination is required to catalyze research on these priorities. To create awareness of and inspire action toward actualizing the top 10 retinoblastoma research priorities in Canada, Canadian Retinoblastoma Research Advisory Board (CRRAB) members developed a wide range of dissemination tools and processes. These resources, co-produced with patients, were instrumental to CRRAB sharing the top 10 priorities internationally to mobilize action toward solving them.

show abstract

“…Heritable retinoblastoma (ie, when the inherited or sporadic RB1 variant is carried in the germline) confers life-long risk of second cancers and 50% chance of passing the variant to offspring; on the other hand, nonheritable retinoblastoma only affects somatic cells and does not confer these risks. 1,2 Although retinoblastoma survival reaches 96%, 3 survivors may experience adverse effects on vision, psychologic and social well-being, and overall health-related quality of life (HRQoL). [4][5][6][7][8] From a medical perspective, the optimal outcomes of retinoblastoma treatment are to first save lives, then eyes, and vision.…”

Section: Introductionmentioning

confidence: 99%

Values of Retinoblastoma Survivors and Parents Regarding Treatment Outcomes: A Qualitative Study

Janic

Vincent

Stinson

et al. 2022

JCO Oncology Practice

Self Cite

View full text Add to dashboard Cite

PURPOSE: Retinoblastoma is an aggressive pediatric eye cancer. Patient-reported outcome measures reveal important insights into how patients perceive their own health. Currently, there is no widely used or validated measure for assessment of retinoblastoma outcomes. The purpose of this research was to uncover which treatment outcomes that retinoblastoma survivors and their parents value, to inform the development of a future measure. METHODS: This qualitative, cross-sectional study included retinoblastoma survivors age 6 years and older and parents of retinoblastoma survivors. Participants who did not demonstrate fluency in English were excluded. Study participants participated in semistructured interviews or focus groups, either in person at The Hospital for Sick Children, Toronto, Canada, or through secure videoconference, between March 3, 2019, and January 25, 2020. Iterative rounds of opening coding, codebook development, and coresearcher analysis were used to identify key emergent themes and subthemes. RESULTS: Seventeen adults participated in six focus groups. Nine pediatric survivors participated in individual interviews. Four common themes emerged from all participant groups: (1) definition of treatment success, (2) enucleation—acceptance and challenges, (3) treatment outcomes to measure, and (4) need for outcome reporting. An additional, unique theme was identified in all pediatric discussions: worries and coping mechanisms. Treatment outcomes deemed valuable were related to the following domains: psychosocial outcomes, daily functioning, functional vision, retinoblastoma education, cosmetic outcomes, and secondary eye conditions. CONCLUSION: This study represents the first stage in the development of a retinoblastoma-specific patient-reported outcome measure. The findings reveal insight into what outcomes are valued by survivors after treatment and offer promise to improve outcomes assessment for retinoblastoma.

show abstract

Clinical audit of retinoblastoma management: a retrospective single-institution study

Cited by 7 publications

References 36 publications

The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma

The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma

EMPOWER Retinoblastoma: Engaging Patient Partners in Solving the Top 10 Priorities for Eye Cancer Research in Canada

Values of Retinoblastoma Survivors and Parents Regarding Treatment Outcomes: A Qualitative Study

Contact Info

Product

Resources

About